Federal State Control of Medical Devices and Risk Categories

1. Key takeaways

Federal state control (supervision) over participants in the circulation of medical devices in Russia is governed by Government Decision No. 1066 of the Russian Federation (30 June 2021), as amended by Government Decision No. 1829 (19 November 2025). The framework divides supervised entities into five risk categories — high / significant / medium / medium-low / low — and determines inspection frequency by category. Supervised entities in the high risk category face the highest frequency of on-site inspections, and the high-risk classification is connected with the manufacture of IVDs and class 3 implantable devices and with the conduct of class 2b and class 3 clinical trials.

For a manufacturer or distributor, the immediate takeaway is that inspection exposure is not uniform and is not accidental: it follows from what the entity does. An organisation manufacturing class 3 implantable devices or running high-class clinical trials should plan its compliance resourcing on the assumption of frequent on-site inspections, while an entity at the low end of the scale still needs documentation ready, because the risk categories are revised and the classification of a specific entity can move. Understanding one’s own category is the precondition for allocating compliance effort sensibly.

2. Legal basis

The supervision framework rests on a government decision, its 2025 amendment, and the statutory foundation of federal law, with the safety monitoring order linking inspection outcomes to the monitoring system. The instruments are summarised below.

Note: the specific inspection frequency for each of the five risk categories and the usage requirements of the Инспектор mobile application have not in this instance been verified item by item against the official regulatory text. This guide therefore states framework-level facts; for specific frequencies, the latest version of the instrument prevails.

3. Expert insights

Insight 1: the objects of inspection are participants in circulation, not only manufacturers. Manufacturing enterprises, authorised representatives, importers, distributors and healthcare organisations may all become inspected parties, each with its own risk category and its own inspection frequency. A supply chain is only as inspected as its least prepared member: an unsatisfactory finding at a distributor or importer can extend scrutiny towards the manufacturer whose device is in circulation. Coordinated readiness across the chain is therefore cheaper than uncoordinated readiness.

Insight 2: the direction of the 2025 amendment is precision. Risk-based classification steers supervisory resources towards high-risk scenarios, and the frequency of on-site inspections for high-risk entities is significantly higher than for medium-low risk entities. The corollary for planning is that identical compliance budgets buy very different levels of assurance depending on where an entity sits in the classification. Entities near the boundary between categories should watch the amendment practice, because a reclassification changes the expected inspection rhythm directly.

Insight 3: inspection and monitoring now form a single line. Under Order No. 540n, RZN may initiate unscheduled supervisory measures on the basis of the outcomes of adverse event handling. This means that the quality of every post-market event handling exercise converts directly into the probability of being inspected. A well-documented adverse event response lowers that probability; a sloppy one raises it. Post-market compliance and inspection readiness are consequently the same budget line, not two.

4. Practical recommendations

Inspection readiness built on the risk category is both cheaper and more defensible than generic readiness.

1. First confirm your own risk category and those of your partners in each link of the circulation chain, then set the frequency of internal self-inspections to match the category rather than to a generic annual cycle.
2. Prepare the adverse event handling file in a form that can be presented at any time, so that an unscheduled inspection finds a complete, indexed record instead of a reconstruction exercise.
3. Monitor the latest version of Government Decision No. 1066 and its amendments, and check the frequency table against your own category whenever it changes.
4. Identify the high-risk scenarios relevant to your operation — IVD manufacturing, class 3 implantable manufacturing, class 2b and class 3 clinical trials — and allocate compliance resources accordingly.
5. Rehearse the receipt of an inspection once a year, including who answers questions, who retrieves documents and who records commitments, so that the first real inspection is not the first rehearsal.

5. Verification checklist

The checklist below confirms that risk category, self-inspection rhythm and documentation are aligned.

• □ Your own risk category (and those of partners in each circulation link) has been confirmed
• □ The frequency of self-inspection matches the risk category
• □ The adverse event handling file can be retrieved at any time
• □ The latest versions of Decision No. 1066 / No. 1829 have been obtained and the frequencies checked
• □ High-risk situations (IVD, class 3 implantable, class 2b / class 3 clinical trials) have been identified
• □ A named owner tracks amendments to the supervision framework

Regulatory information verified as of 29 October 2026.

GRZAN prepares manufacturers, importers and distributors in Russia for federal state control (supervision) inspections, from risk category assessment and self-inspection programmes to inspection-ready adverse event documentation, alongside vigilance and recall support across the post-market cycle. For inspection readiness support, contact us at info@grzanglobal.com.